The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.
Allison Ackerman
No relevant relationships to disclose
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb; Prometheus; Roche/Genentech
Donald P. Lawrence
No relevant relationships to disclose
Anasuya Gunturi
No relevant relationships to disclose
Keith T. Flaherty
Consultant or Advisory Role - Roche/Genentech
Anita Giobbie-Hurder
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche/Genentech (U)
Research Funding - Bristol-Myers Squibb; Roche/Genentech
Nageatte Ibrahim
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb; Prometheus; Roche/Genentech
Daniel C. Cho
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose